Prognostic Factors in Typical and Atypical Pulmonary Carcinoids

REFERENCES

1. 1.↵
   1. Gustafsson BI,
   2. Kidd M,
   3. Chan A,
   4. Malfertheiner MV,
   5. Modlin IM

   Bronchopulmonary neuroendocrine tumors. Cancer. 2008 7 1; 113 1: 5- 21. doi: 10.1002/cncr.23542. pmid:18473355

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Buikhuisen WA,
   2. Tesselaar ME,
   3. van Velthuysen M-L,
   4. Korse CM

   Neuroendocrine tumors of the lung: a comprehensive overview. Int J Endocr Oncol. 2014; 1 1: 71- 79. doi: 10.2217/ije.14.4.

   OpenUrlCrossRef
3. 3.↵
   1. Beasley MB,
   2. Brambilla E,
   3. Travis WD

   The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005 4; 40 2: 90- 7. pmid:15898407

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Naalsund A,
   2. Rostad H,
   3. Strøm EH,
   4. Lund MB,
   5. Strand TE

   Carcinoid lung tumors—incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg. 2011 4; 39 4: 565- 569. doi: 10.1016/j.ejcts.2010.08.036. pmid:20888248

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Rea F,
   2. Rizzardi G,
   3. Zuin A,
   4. et al.

   Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007 2; 31 2: 186- 191. pmid:17140801

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Pape UF,
   2. Jann H,
   3. Müller-Nordhorn J,
   4. et al.

   Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008 7 15; 113 2: 256- 265. doi: 10.1002/cncr.23549. pmid:18506737

   OpenUrlCrossRefPubMedWeb of Science
7. 7.
   1. Strosberg J,
   2. Nasir A,
   3. Coppola D,
   4. Wick M,
   5. Kvols L

   Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009 9; 40 9: 1262- 1268. doi: 10.1016/j.humpath.2009.01.010. pmid:19368957

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Dhall D,
   2. Mertens R,
   3. Bresee C,
   4. et al.

   Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol. 2012 4; 43 4: 489- 495. doi: 10.1016/j.humpath.2011.06.011. pmid:21937080

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Pelosi G,
   2. Rindi G,
   3. Travis WD,
   4. Papotti M

   Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol. 2014 3; 9 3: 273- 284. doi: 10.1097/JTO.0000000000000092. pmid:24518085

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Walts AE,
    2. Ines D,
    3. Marchevsky AM

    Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012 9; 25 9: 1258- 1264. doi: 10.1038/modpathol.2012.81. pmid:22575865

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Edge SB,
    2. Byrd DR,
    3. Compton CC,
    4. Fritz AG,
    5. Greene FL,
    6. Trotti A

    AJCC Cancer Staging Manual. 7th ed. Edge SB, , Byrd DR, , Compton CC, , Fritz AG, , Greene FL, , Trotti A, New York, NY: Springer; 2010.
12. 12.↵
    1. Modlin IM,
    2. Lye KD,
    3. Kidd M. A

    5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 2 15; 97 4: 934- 959. pmid:12569593

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Broaddus RR,
    2. Herzog CE,
    3. Hicks MJ

    Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med. 2003 9; 127 9: 1200- 1203. pmid:12946222

    OpenUrlPubMed
14. 14.↵
    1. Dishop MK,
    2. Kuruvilla S

    Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital. Arch Pathol Lab Med. 2008 7; 132 7: 1079- 1103. doi: 10.1043/1543-2165(2008)132[1079:PAMLTI]2.0.CO;2. pmid:18605764

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Granberg D,
    2. Sundin A,
    3. Janson ET,
    4. Oberg K,
    5. Skogseid B,
    6. Westlin JE

    Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf). 2003 12; 59 6: 793- 799. pmid:14974924

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Yellin A,
    2. Zwas ST,
    3. Rozenman J,
    4. Simansky DA,
    5. Goshen E

    Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J. 2005 11; 7 11: 712- 716. pmid:16308994

    OpenUrlPubMed
17. 17.↵
    1. Oberg K,
    2. Ferone D,
    3. Kaltsas G,
    4. Knigge UP,
    5. Taal B,
    6. Plöckinger U;

    Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology. 2009; 90 2: 209- 213. doi: 10.1159/000183751. pmid:19077379

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Filosso PL,
    2. Ruffini E,
    3. Oliaro A,
    4. Papalia E,
    5. Donati G,
    6. Rena O

    Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002 5; 21 5: 913- 917. pmid:12062286

    OpenUrlCrossRefPubMed
19. 19.↵
    1. van Essen M,
    2. Krenning EP,
    3. Bakker WH,
    4. de Herder WW,
    5. van Aken MO,
    6. Kwekkeboom DJ

    Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007 8; 34 8: 1219- 1227. pmid:17260141

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Filosso PL,
    2. Oliaro A,
    3. Ruffini E,
    4. et al.

    Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol. 2013 10; 8 10: 1282- 1288. doi: 10.1097/JTO.0b013e31829f097a. pmid:24457239

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Fink G,
    2. Krelbaum T,
    3. Yellin A,
    4. et al.

    Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001 6; 119 6: 1647- 1651. pmid:11399686

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Rorstad O

    Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005 3 1; 89 3: 151- 160. pmid:15719376

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Kawahara M,
    2. Kammori M,
    3. Kanauchi H,
    4. et al.

    Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol. 2002 3; 28 2: 140- 146. pmid:11884049

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Zahel T,
    2. Krysa S,
    3. Herpel E,
    4. et al.

    Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch. 2012 3; 460 3: 299- 308. doi: 10.1007/s00428-012-1194-2. pmid:22293945

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Rindi G,
    2. Klersy C,
    3. Inzani F,
    4. et al.

    Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. 2013 12 16; 21 1: 1- 16. doi: 10.1530/ERC-13-0246. pmid:24344249

    OpenUrlAbstract/FREE Full Text